

SPEAKER 1: Yeah, the ODYSSEY trial was the first large scale study that showed a clear, clinical benefit of the PCSK9 inhibitor. And the strongest point, of course, is a reduction in mortality in these post-ACS patients. And what were very good in ODYSSEY was that the patients with the highest background LDL level had the largest benefit on all endpoints, including mortality. I think that is very strong data, and therefore, I think the agent used in ODYSSEY is I think so far the best in post-ACS patients.